INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

On October 6, 2025, Skye issued a press release "announcing the topline data from its 26-week Phase 2a CBeyondâ"¢ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody." The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy." On this n ...